TSN 2898
Alternative Names: TSN-2898Latest Information Update: 28 Jul 2019
At a glance
- Originator Thesan Pharmaceuticals
- Class Antiacnes; Small molecules
- Mechanism of Action Stearoyl-CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne vulgaris
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for clinical-Phase-Unknown development in Acne-vulgaris in USA (Topical, Gel)
- 03 May 2017 Thesan Pharmaceuticals withdraws a phase II trial in Acne vulgaris in USA due to unavailability of the drug (NCT02796066)
- 27 Jun 2016 Clinical trials in Acne vulgaris in USA (Topical) prior to June 2016